Second primary malignancy for early‐stage head and neck squamous cell carcinoma by SEER 17 registries
Oral Diseases · 2025
DOI: 10.1111/odi.15083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Hanqing Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Startup Fund for Talents of Fujian Province.
Abstract (Originalsprache)
Objective
Investigating treatment modalities' association with second primary malignancy risk in early‐stage head and neck squamous cell carcinoma (HNSCC).
Methods
Data of 5‐year survivors of early‐stage (stages I–II, seventh TNM staging manual) HNSCC from 2000 to 2020 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Standardized incidence ratio and excess absolute risk were used to assess second primary malignancy (SPM) development externally. Relative risk was estimated to compare SPM risk within groups. Fine‐Gray's model estimated cumulative incidence of second primary malignancy.
Results
Overall, 8957 5‐year survivors with early‐stage HNSCC were enrolled. Patients receiving definitive radiotherapy had poorer survival than surgery patients. Surgery correlated with lower risk of second primary malignancy (RR = 0.89, 95% CI 0.80–0.99), especially for oropharyngeal squamous cell carcinoma (RR = 0.56, 95% CI 0.39–0.82). Differences in the risk of second primary malignancy among subgroups based on clinical characteristics were not significant. Treatment modalities did not significantly affect risk of second primary malignancy within each subgroup.
Conclusions
Surgery led to better survival and lower risk of second primary malignancy compared to definitive radiotherapy in 5‐year survivors. Incidence and sites of second primary malignancy varied by primary sites, emphasizing targeted long‐term surveillance's importance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Fujian Institute of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
- Fujian Branch Center of National Clinical Research Center for Otorhinolaryngologic Diseases, Fujian Clinical Research Center for Difficult Diseases of Otorhinolaryngology, The First Affiliated Hospital of Fujian Medical…
- National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
ORCID-Profile: Hanqing Lin
Förderung
- Startup Fund for Talents of Fujian Province
Zitieren
APA
Lin, H., Wu, X., Yao, G., Chen, Z., Xu, Y., Lin, G., & Lin, C. (2025). Second primary malignancy for early‐stage head and neck squamous cell carcinoma by SEER 17 registries. Oral Diseases. https://doi.org/10.1111/odi.15083
Vancouver
Lin H, Wu X, Yao G, Chen Z, Xu Y, Lin G, et al. Second primary malignancy for early‐stage head and neck squamous cell carcinoma by SEER 17 registries. Oral Diseases. 2025. doi:10.1111/odi.15083
BibTeX
@article{Lin2025,
author = {Lin, Hanqing and Wu, Xiaobo and Yao, Guangnan and Chen, Zhihong and Xu, Yuanteng and Lin, Gongbiao and Lin, Chang},
title = {Second primary malignancy for early‐stage head and neck squamous cell carcinoma by SEER 17 registries},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15083}
}
EUVIMED